Company intelligence / Profile preview

Macrobian-Biotech

Amsterdam, North Holland, Netherlandsmacrobianbiotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company focuses on pre-clinical research to develop novel treatments for disorders of the midbrain dopamine system, with a particular emphasis on Parkinson’s disease. Research activities are conducted within the Swammerdam Institute of Life Sciences at the University of Amsterdam. No clinical results reported yet as programs are pre-clinical

Therapeutic areas: Neurology
Modalities: Likely small molecules or biologics targeting dopamine system disorders
Industry: Biotech

Drug pipeline

1 asset

MB-101

Pre-clinical

Indications: Parkinson's disease

Partnerships

University of Amsterdam/Swammerdam Institute of Life Sciences collaboration

Beyond the preview

Go deeper on Macrobian-Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macrobian-Biotech.

Explore the full profile